MEN1 and gastrin-producing neuroendocrine tumor: In the case of MEN1, there is no current international consensus on the management of gastrinomas given the high rate of recurrence, lack of benefit from incomplete resection, and the often slow-growing nature of the disease [73], with the NCCN recommending observation and treatment with proton pump inhibitors or exploratory surgery for occult gastrinomas, and JNETS guidelines recommending resection of all functioning pancreatic NETs, including gastrinomas associated with MEN1 [74].